Zynerba Pharmaceuticals to Present at H.C. Wainwright BioConnect Virtual Conference
Zynerba Pharmaceuticals (Nasdaq: ZYNE) announced that CEO Armando Anido will present at the H.C. Wainwright BioConnect Conference from January 10-13, 2022. The presentation will focus on the company's innovative transdermal cannabinoid therapies aimed at treating rare neuropsychiatric disorders such as Fragile X syndrome and autism spectrum disorder. An on-demand webcast will be available starting January 10, 2022, at 7:00 a.m. ET on the company's website, and an archived replay will be accessible for 60 days thereafter.
- None.
- None.
DEVON, Pa., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Armando Anido, Chairman and Chief Executive Officer of Zynerba Pharmaceuticals, will present during the H.C. Wainwright BioConnect Conference being held virtually January 10-13, 2022.
A webcast of the presentation will be available on-demand beginning January 10, 2022, at 7:00 a.m. ET under the Events & Webcasts tab of the Investors section of the Zynerba website at www.zynerba.com. An archived replay will be available on the Company’s website following the event for 60 days.
About Zynerba Pharmaceuticals, Inc.
Zynerba Pharmaceuticals is the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. We are committed to improving the lives of patients and their families living with severe, chronic health conditions including Fragile X syndrome, autism spectrum disorder, and 22q11.2 deletion syndrome. Learn more at www.zynerba.com and follow us on Twitter at @ZynerbaPharma.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the Company’s current expectations. These and other risks are described in the Company’s periodic reports, including the annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, filed with or furnished to the Securities and Exchange Commission and available at www.sec.gov. Any forward-looking statements that the Company makes in this press release speak only as of the date of this press release. The Company assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
Zynerba Contacts
Peter Vozzo
ICR Westwicke
Office: 443.213.0505
Cell: 443.377.4767
Peter.Vozzo@Westwicke.com
FAQ
When will Zynerba Pharmaceuticals present at the H.C. Wainwright BioConnect Conference?
How can I watch the Zynerba Pharmaceuticals presentation online?
What topics will Zynerba Pharmaceuticals cover in their presentation?
What is the focus of Zynerba Pharmaceuticals' therapies?
Will there be a replay of the Zynerba Pharmaceuticals presentation?
